Introduction
Signal transducer and activator of transcription (STAT) family proteins are requisite molecules in the development of T helper subsets. STAT1 and STAT4 are required for the development of Th1 cells that secrete IFNγ and mediate immunity to intracellular pathogens. STAT3 promotes Th17 development and the secretion of IL-17, a cytokine required for immunity to extracellular bacterial and fungal infections. STAT6 is required for the differentiation of Th2 and Th9 cells, which contribute to extracellular parasite immunity. 1 The in vivo function of STAT6 has been defined largely following the generation of gene-deficient mice. Stat6 −/− mice develop normally, breed as homozygotes, but have altered immune responses in vivo. [2] [3] [4] [5] In the absence of STAT6, mice are resistant to the development of allergic inflammation, and have exaggerated responses to inflammatory insults resulting in greater immunity to intracellular pathogens, but greater susceptibility to autoimmune inflammation, with differences in phenotype attributed to different mouse lines with targeted Stat6 alleles. 2, 6 Some of the studies that defined these functions utilized experiments involving adoptive transfer of lymphocytes, or where cells or tumors were adoptively transferred into Stat6 −/− hosts. Whether cells behave normally in these transfer experiments has not been extensively examined.
In experiments to test if deficiency in STAT4 or STAT6 affected development of CTL specific for non-classical MHC molecules, we observed autoreactivity of Stat6 −/− CTL for STAT6-expressing cells. (Fig. 1A-C) . However, we did observe that Stat6 −/− anti-NZB CTL could lyse target cells from Stat4 −/− and BALB/c mice (Fig. 1C) . In contrast, BALB/c and Stat4 −/− responders did not lyse BALB/c, Stat4 −/− or Stat6 −/− cells ( Fig. 1A and B) . Fig. 3A and B) . In Figure 3C , lysis of Stat4 Fig. 2A and B with a phenotype arising from STAT6-deficiency, suggesting that the contribution of anti-STAT6 immunity may be modest.
The contribution of anti-STAT6 CTL responses may be more important in studies of graft rejection. Two reports 14, 15 demonstrated that Stat6 −/− mice demonstrated shorter graft survival times in models of cardiac transplant with minor histocompatibility differences, and where CTLA4-Ig was used to block graft rejection. Although it is possible that some of this increase is due to the increased propensity of Stat6 −/− T cells to develop into inflammatory T cells, it is likely that anti-STAT6 immunity may also be contributing to the observed phenotype.
Stat6
−/− CTL recognized peptides derived from the STAT6 protein. We tested a STAT6 peptide previously shown to be presented by tumor cells 7 and observed the H2-K d restricted CTL recognize Stat6 −/− target cells incubated with the SYWSDRLIL peptide (Fig. 4) 9, 10 it is possible that STAT6-specific CD8 T cells could mediate a graft vs. host response, resulting in background inflammation, apart from the specific responses being studied. Conversely, when STAT6-expressing cells are transferred into Stat6 −/− recipients, it is possible that Stat6 −/− CD8 T cells reactive against STAT6 peptides might eliminate transferred cells, masking some functional activity of the transferred cells. [10] [11] [12] [13] The results from most of these experiments are consistent selected in the thymus. The differences between the phenotypes of Stat4 −/− and Stat6 −/− CTL illustrate that the autoreactive phenomenon described here must be tested empirically for each mutant strain being studied.
In summary, our data illustrate the importance of demonstrating maintenance of self-tolerance in mice made defective in a particular gene by homologous recombination. Particularly in genes that have immune function, where common techniques involve transplantation and adoptive transfer, it is critical to define the ability of T cells to recognize peptides from the targeted proteins as foreign. Failure to do so could result in misinterpretation of how a gene of interest contributes to immune responses.
Material and Methods

Mice. Stat4
−/− and Stat6 −/− mice were generated and backcrossed for at least 10 generations to BALB/c mice as described previously.
3,18 B6.Tla a , B10.BR, C3H/HeJ breeder mice and BALB/c. dm2 spleen cells were the kind gift of Dr James Forman. BALB/c, C57BL/6J, NZB/B1NJ and A/J breeder mice were purchased from The Jackson Laboratory. All animals were bred and housed in the IUSM-Evansville animal facility and procedures were approved by the IUSM IACUC. Where indicated, mice were immunized intraperitoneally with 25 × 10 6 spleen cells in 0.5 mL balanced salt solution, rested for at least 7 d, euthanized, and their spleens removed for the in vitro generation of CTL.
Cell lines and assays. Using specific strain combinations as described, CTL were generated in secondary MLC as described. 19 Briefly, 5 × 10 6 responder and 5 × 10 6 irradiated (3000Rad) stimulator spleen cells were incubated for 6-7 d in RPMI 1640 supplemented with 7-10% fetal bovine serum, 1% l-glutamine and 50 ng/mL 2-mercaptoethanol at 37°C in 7% CO 2 . Some CTL The anti-STAT6 immunity that develops in mice lacking endogenous STAT6 clearly contributes to the increased anti-tumor immunity in Stat6 −/− mice. For example, OstrandRosenberg et al. 16 have shown delayed and reduced primary mammary carcinoma growth in Stat6 −/− mice using 4T1, a BALB/c mammary carcinoma that is usually malignant, non-immunogenic and metastatic. The authors hypothesize that the deletion of the Stat6 gene facilitates development of potent anti-tumor immunity via a CD4 + -independent pathway. Our data suggest that immunization with the H2 d STAT6-expressing tumor might simply stimulate CD8 + CTL specific for H2 d restricted antigens from STAT6-expressing cells, which lyse the cells regardless of expression of tumor antigens. Indeed, Jensen et al. demonstrate that enhanced immunity to 4T1 cells in Stat6 −/− mice is dependent upon the STAT6 peptide used in our studies. 7 Similarly, Kacha et al. 17 show that effector cells from Stat6 −/− mice have increased lytic activity and produce increased levels of IFNγ in response to the H2 d tumor P1.HTR. Thus, it is not clear that these studies actually demonstrate an effect of STAT6 function, but rather may reflect immune responses that are not tolerant to STAT6 peptides presented in the context of MHC I.
It is important to note that "autoreactivity" to a missing self-protein is not a ubiquitous phenomenon. Although there is clearly an anti-STAT6 CTL response in Stat6 −/− mice, there is no corresponding anti-STAT4 CTL response in Stat4 −/− mice. There could be multiple reasons for the restricted nature of these observations. First, not all proteins have MHC class I binding peptides. It is possible that STAT4 peptides do not compete effectively for binding to MHC class I such that no reactive cells are positively selected in the thymus. Alternatively, MHC class I binding peptides from STAT4 might be homologous enough to other endogenous peptides that reactive T cells are negatively lines were re-stimulated weekly with irradiated stimulator cells in supplemented Mishell-Dutton medium that also contained T-cell growth factors from (NH 4 ) 2 SO 4 -precipitated supernatants of phorbol myristic acetate-stimulated EL4.IL2 cells. 20 Generation of concanavalin A (ConA) blast cells (CAB), 51 Cr labeling of target cells, the standard 4-6 h 51 Cr release assay, controls, and the method for determination of the % specific lysis of target cells have been described. 21 Standard error was computed by propagation of errors as previously described. 21 51 Cr release assays for analysis of peptide binding, peptide blocking and antibody blocking were performed using pre-incubations as previously described. 22 RMA-S-D d , T2-D d , E3 and LTKD cell lines were provided by Dr D. Marguiles. RMA-S-L d cell lines were provided by Dr Ted Hansen. Hybridomas producing anti-MHC antibodies were purchased from ATCC. Peptides were purchased from Genemed Synthesis. Flow cytometry analyses of CTL lines was performed as previously described.
19 using anti-CD4 antibody GK1.4 (PharMingen) and anti-CD8α antibody YTS169.4 (kindly provided by Dr. James Forman,) The CTL were CD8 + and CD4 − , as expected.
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